Double-Pronged cell therapy takes on tough lymphoma
NCT ID NCT07344818
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new type of cell therapy that uses a patient's own immune cells, engineered to attack two targets (CD19 and CD20) on lymphoma cells. It aims to see if this approach is safe for people with aggressive B-cell lymphoma that has come back or not responded to prior treatments. The study will enroll 18 adults and is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD19 and CD20 dual-target CAR-T cells (a type of immune cell therapy made from the patient's own blood)
- What this could lead to
- If it works, this could point toward a new treatment option for people with aggressive B-cell lymphoma that has not responded to standard therapy.
- What could go wrong
- This is a very early, small trial (18 people) focused on safety, not yet on effectiveness. The therapy may cause serious side effects or fail to control the cancer long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for R/R AGGRESSIVE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China